Literature DB >> 7984289

Interaction between enantiomers of mianserin and ORG3770 at 5-HT3 receptors in cultured mouse neuroblastoma cells.

A R Kooyman1, R Zwart, P M Vanderheijden, J A Van Hooft, H P Vijverberg.   

Abstract

Stereoselective effects of mianserin and ORG3770 on serotonin 5-HT3 receptors in mouse neuroblastoma N1E-115 cells have been investigated in radioligand binding and in whole-cell voltage clamp experiments. The specific binding of [3H]GR65630 to 5-HT3 recognition sites in N1E-115 cell homogenates is reduced by mianserin and ORG3770 and their enantiomers. The pKi values of the more potent (R)enantiomers of mianserin and ORG3770 are 8.44 and 8.62, respectively. The (R)enantiomers of mianserin and ORG3770 are 15 and 37 times more potent than their respective (S)enantiomers. The racemates are only 1.9 and 3.3 times less potent than the corresponding (R)enantiomers. In voltage clamp experiments the (R)enantiomers block the 5-hydroxytryptamine(5-HT)-induced ion current with pIC50 values of 8.52 for (R)mianserin and 8.26 for the (R)enantiomer of ORG3770. The (R)enantiomers of mianserin and ORG3770 are 24 and 145 times more potent in blocking the 5-HT-induced ion current than their respective (S)enantiomers. The racemates are 6 and 13 times less potent than the corresponding (R)enantiomers. In addition, the block of 5-HT-induced ion current by the (R)enantiomer of ORG3770 is partially reversed by a low concentration of its (S)enantiomer. The results indicate that the two enantiomers block the 5-HT3 receptor-mediated ion current in a mutually dependent manner.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7984289     DOI: 10.1016/0028-3908(94)90081-7

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  13 in total

1.  Mirtazapine alters cue-associated methamphetamine seeking in rats.

Authors:  Steven M Graves; T Celeste Napier
Journal:  Biol Psychiatry       Date:  2010-11-20       Impact factor: 13.382

Review 2.  The non-antiemetic uses of serotonin 5-HT3 receptor antagonists. Clinical pharmacology and therapeutic applications.

Authors:  A J Greenshaw; P H Silverstone
Journal:  Drugs       Date:  1997-01       Impact factor: 9.546

Review 3.  Monoamine reuptake inhibitors in Parkinson's disease.

Authors:  Philippe Huot; Susan H Fox; Jonathan M Brotchie
Journal:  Parkinsons Dis       Date:  2015-02-25

4.  The atypical antidepressant mirtazapine attenuates expression of morphine-induced place preference and motor sensitization.

Authors:  Steven M Graves; Amanda L Persons; Jennifer L Riddle; T Celeste Napier
Journal:  Brain Res       Date:  2012-07-20       Impact factor: 3.252

5.  Mirtazapine : A Review of its Pharmacology and Therapeutic Potential in the Management of Major Depression.

Authors:  R Davis; M I Wilde
Journal:  CNS Drugs       Date:  1996-05       Impact factor: 5.749

6.  A double-blind, fixed blood-level study comparing mirtazapine with imipramine in depressed in-patients.

Authors:  J A Bruijn; P Moleman; P G Mulder; W W van den Broek; A M van Hulst; R C van der Mast; B J van de Wetering
Journal:  Psychopharmacology (Berl)       Date:  1996-10       Impact factor: 4.530

7.  Neuroimaging of mirtazapine enantiomers in humans.

Authors:  Donald F Smith; Søren B Hansen; Steen Jakobsen; Dirk Bender; Hélène Audrain; Mahmoud Ashkanian; Bo S Stork; Luciano Minuzzi; Håkan Hall; Raben Rosenberg
Journal:  Psychopharmacology (Berl)       Date:  2008-06-20       Impact factor: 4.530

Review 8.  Mirtazapine, and mirtazapine-like compounds as possible pharmacotherapy for substance abuse disorders: evidence from the bench and the bedside.

Authors:  Steven M Graves; Roueen Rafeyan; Jeffrey Watts; T Celeste Napier
Journal:  Pharmacol Ther       Date:  2012-08-29       Impact factor: 12.310

9.  [N-methyl-11C]Mirtazapine for positron emission tomography neuroimaging of antidepressant actions in humans.

Authors:  Katalin Marthi; Steen Jakobsen; Dirk Bender; Søren B Hansen; Stefan Bo Smith; Flemming Hermansen; Raben Rosenberg; Donald F Smith
Journal:  Psychopharmacology (Berl)       Date:  2004-07       Impact factor: 4.530

Review 10.  Chirality and drugs used in psychiatry: nice to know or need to know?

Authors:  R M Lane; G B Baker
Journal:  Cell Mol Neurobiol       Date:  1999-06       Impact factor: 5.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.